Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.69 |
| ▸ | FBP1 | P09467 | 2/20 | 0.68 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.68 |
| ▸ | KDR | P35968 | 2/20 | 0.68 |
| ▸ | AURKA | O14965 | 1/20 | 0.68 |
| ▸ | INSR | P06213 | 1/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.68 |
| ▸ | FLT4 | P35916 | 1/20 | 0.68 |
| ▸ | CLK1 | P49759 | 1/20 | 0.68 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.68 |
| ▸ | TEK | Q02763 | 1/20 | 0.68 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.68 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.66 |
| ▸ | RAF1 | P04049 | 1/20 | 0.63 |
| ▸ | BRAF | P15056 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18633104 | 0.90 | EGFR (0.70) | EGFRFBP1ERBB2KDRAURKA | |
| SCHEMBL12788062 | 0.90 | EGFR (0.66) | EGFRFBP1ERBB2KDRAURKA | |
| SCHEMBL19631509 | 0.88 | EGFR (0.64) | EGFRFBP1ERBB2KDRAURKA | |
| SCHEMBL28403915 | 0.88 | EGFR (0.74) | EGFRFBP1ERBB2KDRAURKA | |
| SCHEMBL30124192 | 0.87 | EGFR (0.83) | EGFRFBP1ERBB2KDRAURKA | |
| SCHEMBL8383 | 0.87 | EGFR (0.83) | EGFRFBP1ERBB2KDRAURKA | |
| SCHEMBL29679736 | 0.87 | EGFR (0.83) | EGFRFBP1ERBB2KDRAURKA | |
| SCHEMBL3238800 | 0.87 | EGFR (0.83) | EGFRFBP1ERBB2KDRAURKA | |
| Hydrochloric Acid SCHEMBL28040041 | 0.86 | EGFR (0.81) | EGFRFBP1ERBB2KDRAURKA | |
| SCHEMBL641359 | 0.86 | EGFR (0.75) | EGFRFBP1ERBB2KDRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2018-02-22 | — | — | US | disclosed |
| EP-2634178-B1 | QUINAZOLINE DERIVATIVE AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICATION OF TUMOR CELLS AND PREPARATION METHOD THEREOF | CHINESE ACAD INST CHEMISTRY (CN) | 2016-08-24 | — | — | EP | disclosed |
| EP-2634178-B1 | QUINAZOLINE DERIVATIVE AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICATION OF TUMOR CELLS AND PREPARATION METHOD THEREOF | CHINESE ACAD INST CHEMISTRY (CN) | 2016-08-24 | — | — | EP | disclosed |
| WO-2016123706-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016123706-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | TRILLIUM THERAPEUTICS INC. (CA) | 2016-08-11 | — | — | WO | disclosed |
| US-9233995-B2 | Quinazoline derivatives and quinazoline complex protein kinase inhibitor for inhibiting multiplication of tumor cells and preparation method thereof | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-01-12 | — | — | US | disclosed |
| US-9233995-B2 | Quinazoline derivatives and quinazoline complex protein kinase inhibitor for inhibiting multiplication of tumor cells and preparation method thereof | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-01-12 | — | — | US | disclosed |
| US-9233995-B2 | Quinazoline derivatives and quinazoline complex protein kinase inhibitor for inhibiting multiplication of tumor cells and preparation method thereof | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-01-12 | — | — | US | disclosed |
| EP-2634178-A1 | QUINAZOLINE DERIVATIVE AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICATION OF TUMOR CELLS AND PREPARATION METHOD THEREOF | Institute Of Chemistry, Chinese Academy Of Sciences (CN) | 2013-09-04 | — | — | EP | disclosed |
| EP-2634178-A1 | QUINAZOLINE DERIVATIVE AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICATION OF TUMOR CELLS AND PREPARATION METHOD THEREOF | Institute Of Chemistry, Chinese Academy Of Sciences (CN) | 2013-09-04 | — | — | EP | disclosed |
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCE (CN) | 2013-08-29 | — | — | US | disclosed |
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCE (CN) | 2013-08-29 | — | — | US | disclosed |
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCE (CN) | 2013-08-29 | — | — | US | disclosed |
| CN-102452988-A | Quinazoline derivative and preparation method thereof | CHINESE ACAD INST CHEMISTRY | 2012-05-16 | — | — | CN | disclosed |
| US-7078409-B2 | Fused quinazoline derivatives useful as tyrosine kinase inhibitors | BETA PHARMA, INC. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20040048883-A1 | Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors | BETA PHARMA, INC. | 2004-03-11 | — | — | US | disclosed |
| WO-2003082830-A1 | NOVEL FUSED QUINAZOLINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | BETA PHARMA, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180050993-A1 | NOVEL FLUORINATED DERIVATIVES AS EGFR INHIBITORS USEFUL FOR TREATING CANCERS | EGFR, ERBB2, ERBB4 | EGFR 1/4885FBP1 213/4885ERBB2 2/4885 |
| US-20040048883-A1 | Novel fused quinazoline derivatives useful as tyrosine kinase inhibitors | ABL1, ERBB2, CNKSR1 | EGFR 82/4885FBP1 2723/4885ERBB2 2/4885 |
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | MAP3K21, MAP3K15, MAP3K14 | EGFR 225/4885FBP1 2926/4885ERBB2 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.